HRS-7058 + SHR-1316 + platinum-containing doublet chemotherapy

HRS-7058 + SHR-1316 + platinum-containing doublet chemotherapy is a combination regimen under investigation for cancer treatment, particularly non-small cell lung cancer (NSCLC). HRS-7058 and SHR-1316 are investigational agents; while specific mechanisms for these two drugs are not detailed in the provided sources, they are likely targeted therapies or immunotherapies based on naming conventions. Platinum-containing doublet chemotherapy refers to a standard regimen that combines a platinum agent (such as cisplatin or carboplatin) with a third-generation cytotoxic drug (such as docetaxel, paclitaxel, vinorelbine, gemcitabine, irinotecan, pemetrexed, or S-1). This combination exploits synergistic effects between agents with different mechanisms of action to improve response rates in cancers like NSCLC[1][2][5]. The addition of novel agents such as immune checkpoint inhibitors to this backbone is an emerging strategy in oncology[3][4].

Other names

platinum-containing doublet chemotherapyplatinum doublet therapy